WO2003061475A1 - Method and device for monitoring analyte concentration by use of differential osmotic pressure measurement - Google Patents
Method and device for monitoring analyte concentration by use of differential osmotic pressure measurement Download PDFInfo
- Publication number
- WO2003061475A1 WO2003061475A1 PCT/DK2003/000036 DK0300036W WO03061475A1 WO 2003061475 A1 WO2003061475 A1 WO 2003061475A1 DK 0300036 W DK0300036 W DK 0300036W WO 03061475 A1 WO03061475 A1 WO 03061475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compartment
- pressure
- compartments
- glucose
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N13/04—Investigating osmotic effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N7/00—Analysing materials by measuring the pressure or volume of a gas or vapour
- G01N7/10—Analysing materials by measuring the pressure or volume of a gas or vapour by allowing diffusion of components through a porous wall and measuring a pressure or volume difference
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/076—Permanent implantations
Definitions
- This invention relates to biological sensors, more specifically to implantable sensors for monitoring species such as glucose, in a living creature, for example, in the human or animal body. Further specifically, but not exclusively, this invention relates to biological sensors for the detection of glucose in blood or tissue of a diabetic patient.
- Diabetic patients can improve their life quality expectancy by maintaining their blood glucose concentration close to the natural level of a healthy person. To achieve this natural concentration, diabetes patients must frequently measure their glucose concentration, and adjust their insulin dosing in accordance with the measured concentration.
- a blood sample is obtained for measurement of blood glucose concentration, and there are a number of different glucose test kits on the market based on measurement on blood samples. The disadvantage of these test kits is the need to take a blood sample, which must be collected from a suitable place on the body.
- Biological sensors in the form of implantable devices are also known in the art and include electrochemical devices and optical devices based on the creation of an electrical or optical signal by the consumption of the compound detected by the analysis.
- An example is US 6,011,984, which discloses methods utilising an amplification component.
- the sensitivity and the responsivity of such devices are influenced by the formation of a bio film, for example, by fibrous encapsulation of the device, which reduces the transport rate of the compound to the sensor.
- other mechanisms which cause deterioration of the sensor performance of implanted devices may also be present, for example, membrane de- lamination and degradation, enzyme degradation and electrode passivation.
- US 5,337,747 discloses an implantable device comprising two measurement chambers each of which comprises an internal measurement chamber isolated from its surroundings by a glucose-impermeable membrane for the first measurement chamber, and by a glucose-permeable membrane which is impermeable to molecules larger than glucose for the second measurement chamber.
- Each measurement chamber is connected to a pressure sensor and linked to an electronic system provided for informing the environment outside the organism of the value of the pressure measured in each of the two measurement chambers. The pressure difference between the two measurement chambers is interpreted as the osmotic pressure, and this pressure will correspond to a specific level of glucose.
- the two chambers that constitute the implantable device of US 5,337,747 are in contact with the surroundings at two different locations due to their side- by-side arrangement. This might result in significant detection errors in cases where the conditions (level of glucose, bio fouling tendency etc.) are different at the two locations.
- Another problem is the possibly increased tendency for bio fouling of the glucose-impermeable membrane as compared to the glucose-permeable membrane. This increased tendency for bio fouling will change the transport characteristics of the glucose-impermeable membrane and, thus, increase the need for frequent re- calibration of the device, or replacement of the device.
- the measurement principle disclosed with this invention is not limited to implanted devices in diabetic patients for measuring glucose concentration, but could be used in many other applications.
- the basic idea is used for measuring species in locations which are difficult to access, and where the physical- and chemical conditions vary over time. This could be the measurement of the glucose concentration in a bioreactor or in fruit juice etc.
- the object of this invention is achieved by having two compartments, one of them at least partially defined to the exterior by a first set of barriers permeable for a set of species, the other compartment separated from the first compartment by a second set of barriers permeable only for a subset of the species, only a subset of species that permeates into the first compartment permeates further on into the other compartment .
- the membranes are connected in a serial manner and, thus, only the glucose-permeable membrane is exposed to bio fouling from species in the surroundings, which cannot permeate through the first set of barriers.
- the serial arrangement of the membranes alleviates the problems due to inhomogeneity, as only one compartment is exposed to the surroundings .
- the permeability of the two sets of barriers cause a specific species to be able to permeate into the first compartment, but not into the other compartment. This is achieved in that the first set of barriers is permeable for species up to and including the size of a specific molecule, and the second set of barriers is permeable for species below the size of same specific molecule.
- some of the compartments are filled with a known concentration of species, unable to permeate through the barrier defining the compartment .
- these compartments work as reference compartments, the determination of the concentration of a specific species occurring through comparison with the reference compartments .
- the permeability of the two sets of barriers is such that glucose will be able to permeate into one of the compartments, but not into the other compartment.
- a sensor specific for detecting the concentration of glucose in a sample is achieved.
- the pressure difference between the two compartments is detected, so that a value corresponding to the concentration of species permeating into one of the compartments, but not into the other, is obtained.
- a separate pressure sensor detects the pressure exterior to the two compartments. The influence of pressure variations due to conditions external to the device can hereby be compensated.
- the pressure sensing is at least partly formed as a deflection measurement of a flexible compartment, which will increase or decrease in volume when the pressure in the compartment increases or decreases .
- - Fig. 1 a principal embodiment of the invention showing two compartments, each with a separate barrier.
- - Fig. 2 a principal embodiment of a device, where one of the compartments is divided into multiple reference compartments.
- - Fig. 3 a principal embodiment of a device having a structure in the form of a disc.
- - Fig. 4 an exploded view of the principal device of fig. 3.
- - Fig. 5 an exploded view of the principal device of fig. 3, where the barriers are supported by a mechanical structure .
- - Fig. 6 Diagram with simulation results for the performance of a device .
- Figure 1 shows a sectional view of a device, where two compartments 1 and 2 are stacked on a base plate 3. A perspective view of the same device is shown in figure 3.
- the device is implantable into the human body, and is suitable for detecting the glucose level in blood or interstitial fluid.
- Compartment 1 is sealed to the exterior by the ring member 4 and by a barrier 7, and compartment 2 is sealed to the exterior by ring member 5 and base plate 3.
- a barrier 6 seals the two compartments 1 and 2 from each other.
- Membranes with a specific Molecular Weight Cut Off (MWCO) form each of the barriers 6 and 7.
- the membrane forming the barrier 6 has an MWCO just below the size of the glucose molecule
- the membrane forming the barrier 7 has an MWCO just above the size of the glucose molecule. This means, that only species with the size of the glucose molecule or below will penetrate from the exterior into compartment 1, and that only species with a size below the glucose molecule will penetrate from compartment 1 into compartment 2.
- the osmotic pressure will then appear over the membrane forming the barrier 6, between the two compartments, and two independent pressure sensors 8 and 9 detect the pressure in each compartment.
- the two pressure sensors 8 and 9 could be substituted with a differential pressure sensor, which is capable of detecting the pressure difference between the two compartments 1 and 2.
- An additional pressure sensor 10 is for the purpose of detecting the surrounding pressure, e.g. the pulse beat and exterior pressure variations can thus be taken into account .
- Figure 4 shows an exploded view of figure 3, the ring shape of each element 3-7 becoming more visible.
- the volume of compartment 1 is formed by the internal diameter of the ring shaped element 4 and by the height of element 4.
- the volume of compartment 2 is formed by the internal diameter of the ring shaped element 5 and by the height of element 5.
- the device of figure 4 could consist of ring shaped elements 4 and 5 with an inner diameter of 500 ⁇ m and a height of 240 ⁇ m.
- the membrane 7 could be a 500 Da Biotech Cellulose Ester Membrane from Spectrum Laboratories Inc . , meaning that the membrane has an MWCO of 500 g/mol . This size will allow the molecule glucose to permeate the membrane, and hence enter the compartment 1.
- the membrane 6 could be a 100 Da Biotech Cellulose Ester Membrane from Spectrum Laboratories Inc., meaning that the membrane has an MWCO of 100 g/mol. This size will prevent glucose from permeating the membrane.
- Curve 12 shows the glucose concentration in blood or interstitial fluid, varying with the highest rate possible in the human body.
- Curve 13 indicates the glucose level as given by the device, and curve 14 is the difference between the actual glucose level and the detected glucose level. The difference is within ⁇ 1 mM, which is regarded as an acceptable deviation.
- Figure 5 shows a device similar to that of figure 4, only with a rigid element 11 on either side of each membrane.
- the element 11 must have no influence on the MWCO of the membranes.
- the purpose of this rigid element is to minimise the deflection of the membrane, due to the pressure difference across it. With less deflection of the membranes, the volume of the compartments will be less dependent of the pressure differences, and less amount of species has to permeate through the membranes to yield the equilibrium pressure (osmotic pressure) , which makes the response time of the device shorter and, thus, the device more accurate.
- the pressure sensors can be used as previously described.
- the pressure sensors used in the device shown in figure 4 and 5 might be substituted with a deflection sensor, where the deflection of the membrane then corresponds to the concentration of a given compound.
- Figure 2 shows a device in a 3D-view, where the bottom compartment 2 is divided into a number of compartments
- the top compartment 1 is defined to the exterior by a membrane 7 and to the bottom compartment by a membrane 6, in the same way as described for figure 1.
- the bottom part itself is divided into a number of compartments, here three, each containing a different and known concentration of a given compound.
- the compound in each of the compartments 2a-c could be glucose, and the membrane 6 should have an MWCO below the size of the glucose molecule.
- the differential pressure between compartment 1 and each of 2 will vary from each other.
- the compartment 2 with a pressure equal or close to that of compartment 1 can be determined, and hence the concentration of the given compound in compartment 1.
- the pressure sensor can hereby be substituted with a simple qualitative pressure detector, only capable of detecting the direction of a pressure difference.
- the device can be used as an implantable device, the device may then be powered and data collected from an external device.
- established techniques for biomedical telemetry can be used, e.g. inductively coupled load shift keying or LC resonance frequency modulation.
- the signal can also be transferred optically using infrared light, e.g. by modulation of an infrared
- LED or laser diode or by imaging the inflation/deflation of flexible compartments of the implanted device according to the difference in pressure of the compartments and the external tissue and fluids.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/501,746 US20050154272A1 (en) | 2002-01-23 | 2003-01-21 | Method and device for monitoring analyte concentration by use of differential osmotic pressure measurement |
DE10392210T DE10392210T5 (en) | 2002-01-23 | 2003-01-21 | Method and device for monitoring an analytical concentration by means of an osmosis differential pressure measurement |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200200120 | 2002-01-23 | ||
DKPA200200120 | 2002-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003061475A1 true WO2003061475A1 (en) | 2003-07-31 |
Family
ID=27589017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2003/000036 WO2003061475A1 (en) | 2002-01-23 | 2003-01-21 | Method and device for monitoring analyte concentration by use of differential osmotic pressure measurement |
Country Status (3)
Country | Link |
---|---|
US (1) | US20050154272A1 (en) |
DE (1) | DE10392210T5 (en) |
WO (1) | WO2003061475A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004107972A1 (en) * | 2003-06-10 | 2004-12-16 | Lifecare As | Sensor in vivo measurement of osmotic changes |
EP1544598A1 (en) | 2003-12-18 | 2005-06-22 | Xerox Corporation | Osmotic reaction detector for monitoring biological and non-biological reactions |
GB2446247A (en) * | 2007-11-27 | 2008-08-06 | Robert Joseph Wagener | Implantable valve for the control of an insulin pump |
US7553669B2 (en) | 2003-12-18 | 2009-06-30 | Palo Alto Resaerch Center Incorporated | Osmotic reaction detector for monitoring biological and non-biological reactions |
US7666680B2 (en) | 2004-12-20 | 2010-02-23 | Palo Alto Research Center Incorporated | Osmotic reaction detector for detecting biological and non-biological reactions |
DE102015108644A1 (en) * | 2015-06-01 | 2016-12-01 | Biotronik Se & Co. Kg | Cross sensitivity compensated biosensor |
CN108535136A (en) * | 2018-04-25 | 2018-09-14 | 中国人民解放军空军工程大学 | A kind of concrete gas testing permeability device and method |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
EP2239566B1 (en) | 2003-12-05 | 2014-04-23 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
WO2007120381A2 (en) | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
US8126554B2 (en) * | 2006-05-17 | 2012-02-28 | Cardiac Pacemakers, Inc. | Implantable medical device with chemical sensor and related methods |
US20200037875A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7734349B2 (en) * | 2007-07-18 | 2010-06-08 | Cardiac Pacemakers, Inc. | Osmometric heart monitoring device and methods |
PL2185910T3 (en) * | 2007-08-20 | 2018-12-31 | Lifecare As | Apparatus and method for measuring augmented osmotic pressure in a reference cavity |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
DE102014210440B4 (en) * | 2014-06-03 | 2018-07-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | glucose sensor |
EP2974656A1 (en) * | 2014-07-14 | 2016-01-20 | Universität Zürich | Device for measuring the concentration of an analyte in the blood or tissue of an animal or a human, particularly a premature infant, in a self-calibrating manner |
US10716500B2 (en) | 2015-06-29 | 2020-07-21 | Cardiac Pacemakers, Inc. | Systems and methods for normalization of chemical sensor data based on fluid state changes |
CN108968976B (en) | 2017-05-31 | 2022-09-13 | 心脏起搏器股份公司 | Implantable medical device with chemical sensor |
CN109381195B (en) | 2017-08-10 | 2023-01-10 | 心脏起搏器股份公司 | Systems and methods including electrolyte sensor fusion |
CN109419515B (en) | 2017-08-23 | 2023-03-24 | 心脏起搏器股份公司 | Implantable chemical sensor with staged activation |
CN109864746B (en) | 2017-12-01 | 2023-09-29 | 心脏起搏器股份公司 | Multimode analyte sensor for medical devices |
CN109864747B (en) | 2017-12-05 | 2023-08-25 | 心脏起搏器股份公司 | Multimode analyte sensor optoelectronic interface |
EP4217493A4 (en) * | 2020-09-24 | 2024-04-10 | Univ Cincinnati | Solute-phase electrochemical aptamer sensors with rapid time-to-measurement |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4538616A (en) * | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US5337747A (en) * | 1989-10-06 | 1994-08-16 | Frederic Neftel | Implantable device for estimating glucose levels |
US5388449A (en) * | 1993-07-06 | 1995-02-14 | Leveen; Harry H. | Osmolarity sensor |
WO2001035928A1 (en) * | 1999-11-17 | 2001-05-25 | Microchips, Inc. | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6268161B1 (en) * | 1997-09-30 | 2001-07-31 | M-Biotech, Inc. | Biosensor |
WO2001064344A2 (en) * | 2000-03-02 | 2001-09-07 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
WO2002004918A2 (en) * | 2000-07-12 | 2002-01-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Nanoporous membrane immunosensor |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3011984A (en) * | 1957-06-14 | 1961-12-05 | Exxon Research Engineering Co | Oxonation of butyl rubber and covulcanization products of same with natural rubber or butadiene-styrene copolymer |
US3869364A (en) * | 1973-01-05 | 1975-03-04 | Vast Associates Inc J | System for inhibiting attack on a ferrous anode electrode in an electrodialytic cell |
US3994799A (en) * | 1973-04-17 | 1976-11-30 | Yao Shang J | Blood and tissue detoxification apparatus |
US3905886A (en) * | 1974-09-13 | 1975-09-16 | Aqua Chem Inc | Ultrafiltration and electrodialysis method and apparatus |
US3964985A (en) * | 1974-10-29 | 1976-06-22 | Ionics, Incorporated | Electrodialysis apparatus and process for ion modification |
US4028931A (en) * | 1976-02-13 | 1977-06-14 | Cardio Pulminary Laboratory Research Foundation | Osmotic pressure sensing head |
US4475556A (en) * | 1983-01-03 | 1984-10-09 | Reiff Theodore R | Rapid measurement of colloid osmotic equilibrium pressure |
US4603699A (en) * | 1984-11-20 | 1986-08-05 | Himpens Jacques M | Apparatus and method for measuring osmotic pressure in situ |
US4608048A (en) * | 1984-12-06 | 1986-08-26 | Alza Corporation | Dispensing device with drug delivery patterns |
US4822336A (en) * | 1988-03-04 | 1989-04-18 | Ditraglia John | Blood glucose level sensing |
US5240713A (en) * | 1991-09-27 | 1993-08-31 | Alza Corporation | Dual rate agent delivery device |
DE4219207C2 (en) * | 1992-06-12 | 1996-06-13 | Guenter K Dr Dr Wiese | Automatically expanding tissue expander |
-
2003
- 2003-01-21 WO PCT/DK2003/000036 patent/WO2003061475A1/en not_active Application Discontinuation
- 2003-01-21 DE DE10392210T patent/DE10392210T5/en not_active Withdrawn
- 2003-01-21 US US10/501,746 patent/US20050154272A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4538616A (en) * | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US5337747A (en) * | 1989-10-06 | 1994-08-16 | Frederic Neftel | Implantable device for estimating glucose levels |
US5388449A (en) * | 1993-07-06 | 1995-02-14 | Leveen; Harry H. | Osmolarity sensor |
US6268161B1 (en) * | 1997-09-30 | 2001-07-31 | M-Biotech, Inc. | Biosensor |
WO2001035928A1 (en) * | 1999-11-17 | 2001-05-25 | Microchips, Inc. | Microfabricated devices for the delivery of molecules into a carrier fluid |
WO2001064344A2 (en) * | 2000-03-02 | 2001-09-07 | Microchips, Inc. | Microfabricated devices for the storage and selective exposure of chemicals and devices |
WO2002004918A2 (en) * | 2000-07-12 | 2002-01-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Nanoporous membrane immunosensor |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276028B2 (en) | 2003-06-10 | 2007-10-02 | Lifecare As | Sensor in vivo measurement of osmotic changes |
WO2004107972A1 (en) * | 2003-06-10 | 2004-12-16 | Lifecare As | Sensor in vivo measurement of osmotic changes |
US7794662B2 (en) | 2003-12-18 | 2010-09-14 | Palo Alto Research Center Incorporated | Osmotic reaction detector for monitoring biological and non-biological reactions |
EP1544598A1 (en) | 2003-12-18 | 2005-06-22 | Xerox Corporation | Osmotic reaction detector for monitoring biological and non-biological reactions |
JP2005181329A (en) * | 2003-12-18 | 2005-07-07 | Xerox Corp | Osmotic reaction detector for monitoring biological and non-biological reactions |
JP4643983B2 (en) * | 2003-12-18 | 2011-03-02 | ゼロックス コーポレイション | Osmotic reaction detector for observing biological and non-biological reactions |
US7851226B2 (en) | 2003-12-18 | 2010-12-14 | Xerox Corporation | Osmotic reaction detector for monitoring biological and non-biological reactions |
US7553669B2 (en) | 2003-12-18 | 2009-06-30 | Palo Alto Resaerch Center Incorporated | Osmotic reaction detector for monitoring biological and non-biological reactions |
US7615375B2 (en) | 2003-12-18 | 2009-11-10 | Xerox Corporation | Osmotic reaction cell for monitoring biological and non-biological reactions |
US7666680B2 (en) | 2004-12-20 | 2010-02-23 | Palo Alto Research Center Incorporated | Osmotic reaction detector for detecting biological and non-biological reactions |
US7790111B2 (en) | 2004-12-20 | 2010-09-07 | Palo Alto Research Center Incorporated | Osmotic reaction detector for detecting biological and non-biological reactions |
GB2446247B (en) * | 2007-11-27 | 2008-12-17 | Robert Joseph Wagener | Homeostatic insulin pump |
GB2446247A (en) * | 2007-11-27 | 2008-08-06 | Robert Joseph Wagener | Implantable valve for the control of an insulin pump |
DE102015108644A1 (en) * | 2015-06-01 | 2016-12-01 | Biotronik Se & Co. Kg | Cross sensitivity compensated biosensor |
US10274408B2 (en) | 2015-06-01 | 2019-04-30 | Biotronik Se & Co. Kg | Cross-sensitivity-compensated biosensor |
CN108535136A (en) * | 2018-04-25 | 2018-09-14 | 中国人民解放军空军工程大学 | A kind of concrete gas testing permeability device and method |
Also Published As
Publication number | Publication date |
---|---|
US20050154272A1 (en) | 2005-07-14 |
DE10392210T5 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050154272A1 (en) | Method and device for monitoring analyte concentration by use of differential osmotic pressure measurement | |
US11931145B2 (en) | Orthogonally redundant sensor systems and methods | |
EP1455641B1 (en) | Method and device for monitoring analyte concentration by optical detection | |
US5833603A (en) | Implantable biosensing transponder | |
KR102250989B1 (en) | Methods and systems for improving the reliability of orthogonally redundant glucose sensors | |
US4832034A (en) | Method and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids | |
US7041057B1 (en) | Tissue interface device | |
US20040180391A1 (en) | Sliver type autonomous biosensors | |
US20050221276A1 (en) | Sensor system | |
US20100160749A1 (en) | Implantable optical glucose sensing | |
CN100475129C (en) | Sensor for vivo measurement of osmotic changes | |
CA2743572A1 (en) | Devices, systems, methods and tools for continuous analyte monitoring | |
Fogt | Continuous ex vivo and in vivo monitoring with chemical sensors | |
US8790591B2 (en) | In vitro point-of-care sensor and method of use | |
KR20220027985A (en) | Sensor module for multi-parameter analysis of media | |
KR102578444B1 (en) | Needle-type Biosensor | |
Krushinitskaya | Osmotic sensor for blood glucose monitoring applications | |
JP2018149157A (en) | Biological information acquisition system and biological information acquisition method | |
WO2002078532A1 (en) | Implantable sensor | |
US20210137430A1 (en) | Fully implantable sensor element and method for detecting at least one analyte in a body fluid | |
EP2319394A1 (en) | Non-invasive device and method for monitoring analytes in biological samples | |
Baldini et al. | Carbon dioxide, oxygen, and pH detection in animal adipose tissue by means of extracorporeal microdialysis | |
US20140311925A1 (en) | In vitro point-of-care sensor and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BA BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HR HU IL IN IS JP KR KZ LT LU LV MD MK MX NO NZ PL PT RO RU SE SG SK TR UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
RET | De translation (de og part 6b) |
Ref document number: 10392210 Country of ref document: DE Date of ref document: 20041223 Kind code of ref document: P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10392210 Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10501746 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |